Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Chimerix: Thinking on the Stock in the Aftermath of Results from the AdVise Trial (CMRX, $4.95)

Overview

In a report published on April 14th I recommended purchasing Chimerix at a†price of $5.67. The catalyst for my recommendation…
Read more…